# QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

> **NCT06715124** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Quanta Therapeutics** · enrollment: 237 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QTX3544
- **COMBINATION_PRODUCT:** Cetuximab

## Key facts

- **NCT ID:** NCT06715124
- **Lead sponsor:** Quanta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-14
- **Primary completion:** 2027-01-02
- **Final completion:** 2029-01-02
- **Target enrollment:** 237 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715124, "QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06715124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*